Investment & Fund Management

PEP-Therapy, a biotech company based in Paris, is focused on developing targeted therapies for severe diseases, particularly cancer. The company was founded by Angelita Rebollo and a team of scientists from prestigious French research institutions, aiming to translate groundbreaking research into effective medical treatments. Rebollo's innovative approach involves blocking specific protein functions that lead to the transformation of healthy cells into cancerous ones, thereby allowing for targeted destruction of cancer cells without harming healthy ones. This method is expected to significantly reduce the side effects commonly associated with traditional chemotherapy.

To support its mission, PEP-Therapy received EUR 1 million in funding from Quadrivium 1, the first French investment fund dedicated to seed funding for life sciences and digital technology projects linked to French academic research institutions. This funding is crucial for the company as it seeks to develop its therapies and bring them to market. The establishment of Quadrivium 1 represents a pioneering effort in France, inspired by successful models in the United States and the UK, where academic research has been effectively commercialized through spinout companies.

The investment from Quadrivium 1, which has now reached a total of EUR 56 million following additional support from the European Investment Fund, is part of a broader initiative under the EU’s Investment Plan for Europe. This funding not only aids PEP-Therapy in its development efforts but also sets a precedent for future academic spinouts in France, potentially transforming the landscape of biotech innovation in the country.